Pharmaceuticals India

India Vaccine Adjuvants Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

India Vaccine Adjuvants Market Industry Trends and Forecast to 2034: Segmented by (Type, Application, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

India · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $16.0 Mn Placeholder estimate
Estimate 2025 $17.7 Mn 1.9% of the global market
Projected 2034 $43.9 Mn 147.6% Adds $26.2 Mn over 9 forecast years
CAGR 2025–2034 10.6% Faster than 44% of 180 Pharmaceuticals markets here
Key players 5
  • India is 1.9% of the global market.
  • In APAC, the largest is China at $75.0 Mn.
  • Fastest growing: India (this report) at 10.6% a year.
  • India ranks 3rd of 10 by size in APAC.

Market size projection

India

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$26.2 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Vaccine Adjuvants Market market size by year, India
YearMarket sizeChange that yearSince 2025
2024 (estimate) $16.0 Mn — —
2025 (base) $17.7 Mn +$1.7 Mn —
2026 (forecast) $19.6 Mn +$1.9 Mn +10.6%
2027 (forecast) $21.7 Mn +$2.1 Mn +22.3%
2028 (forecast) $24.0 Mn +$2.3 Mn +35.3%
2029 (forecast) $26.5 Mn +$2.5 Mn +49.6%
2030 (forecast) $29.4 Mn +$2.8 Mn +65.5%
2031 (forecast) $32.5 Mn +$3.1 Mn +83%
2032 (forecast) $35.9 Mn +$3.4 Mn +102.4%
2033 (forecast) $39.7 Mn +$3.8 Mn +123.9%
2034 (forecast) $43.9 Mn +$4.2 Mn +147.6%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

India Vaccine Adjuvants Market Analysis at a glance
Market size, 2025$17.7 Mn placeholder estimate
Forecast, 2034$43.9 Mn placeholder estimate
Growth (CAGR), 2025–203410.6% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsType and application (see all)
Key playersGSK PLC, Novavax, Croda International PLC, SEPPIC (Air Liquide), Dynavax Technologies (see all)
Regulator in IndiaCDSCOSource: Central Drugs Standard Control Organisation. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The India Vaccine Adjuvants Market Analysis Executive Summary

Vaccine adjuvants are ingredients added to vaccines to make the immune response stronger and longer-lasting.

Key segments of the vaccine Adjuvants market include type (Aluminum Salts, Emulsions and Saponin-Based) and application (Human Vaccines and Veterinary Vaccines).

Bar chart: India Vaccine Adjuvants market size, 2024–2034, placeholder estimates. $16.0 Mn in 2024, $17.7 Mn in 2025 and $43.9 Mn in 2034, 10.6% CAGR.
India Vaccine Adjuvants market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

India Vaccine Adjuvants Market Dynamics

Market Growth Drivers

More surgery and intensive care, rising infection risks, new specialty medicines and the growth of hospital pharmacy services are driving the vaccine Adjuvants market.

Opportunity

Ready-to-use formulations, biosimilars and supply security programmes give the vaccine Adjuvants market room to grow.

Market Restraints

Drug shortages, price controls, generic competition and strict hospital budgets hold back the vaccine Adjuvants market.

Competitive Landscape for Vaccine Adjuvants Market in India

The vaccine Adjuvants market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Vaccine Adjuvants Market in India

Vaccine Adjuvants in India: rules and payment

New drugs and clinical trials need approval from the Central Drugs Standard Control Organisation (CDSCO), headed by the Drugs Controller General of India.⁠[1] Ayushman Bharat PM-JAY gives eligible families hospital cover of up to ₹5 lakh a year.⁠[2]

[1] Central Drugs Standard Control Organisation. Checked 14 Nov 2026.

[2] National Health Authority (PM-JAY). Checked 14 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for vaccine Adjuvants. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in India.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Vaccine Adjuvants right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Vaccine Adjuvants in context

India compared

  • Health spending per person: 85 US$ per person (2023). World: 1,317 US$ per person (2023). 10th highest of the 15 countries we cover in APAC.[1]
  • Doctors: 0.72 per 1,000 people (2020). World: 1.86 per 1,000 people (2022). 11th highest of the 15 countries we cover in APAC.[2]
  • People aged 65 and over: 7.4% of people (2025). World: 10.4% of people (2025). 11th highest of the 16 countries we cover in APAC.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 15 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 16 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 16 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Vaccine Adjuvants market in India?
Placeholder estimate: about $17.7 Mn in 2025, rising to about $43.9 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Vaccine Adjuvants market in India growing?
Placeholder estimate: about 10.6% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Vaccine Adjuvants market report cover?
The report splits the market by type (Aluminum Salts, Emulsions, Saponin-Based, TLR Agonists) and application (Human Vaccines, Veterinary Vaccines).
Who are the key players in the Vaccine Adjuvants market?
Key players include GSK PLC, Novavax, Croda International PLC, SEPPIC (Air Liquide) and Dynavax Technologies.
What is driving the Vaccine Adjuvants market?
More surgery and intensive care, rising infection risks, new specialty medicines and the growth of hospital pharmacy services are driving the vaccine Adjuvants market.
Who regulates Vaccine Adjuvants in India?
New drugs and clinical trials need approval from the Central Drugs Standard Control Organisation (CDSCO), headed by the Drugs Controller General of India. Source: Central Drugs Standard Control Organisation. Checked 14 Nov 2026.
How is healthcare paid for in India?
Ayushman Bharat PM-JAY gives eligible families hospital cover of up to ₹5 lakh a year. Source: National Health Authority (PM-JAY). Checked 14 Nov 2026.
How much research is published on Vaccine Adjuvants?
PubMed lists 807 papers on Vaccine Adjuvants added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in India

See all

Related on vaccines and biologics and biosimilars

See the topic